全文获取类型
收费全文 | 884篇 |
免费 | 124篇 |
国内免费 | 14篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 80篇 |
妇产科学 | 6篇 |
基础医学 | 74篇 |
口腔科学 | 3篇 |
临床医学 | 430篇 |
内科学 | 252篇 |
皮肤病学 | 4篇 |
神经病学 | 16篇 |
特种医学 | 2篇 |
外科学 | 36篇 |
综合类 | 67篇 |
现状与发展 | 1篇 |
预防医学 | 16篇 |
眼科学 | 2篇 |
药学 | 19篇 |
中国医学 | 5篇 |
肿瘤学 | 8篇 |
出版年
2024年 | 1篇 |
2023年 | 15篇 |
2022年 | 23篇 |
2021年 | 33篇 |
2020年 | 45篇 |
2019年 | 40篇 |
2018年 | 53篇 |
2017年 | 60篇 |
2016年 | 45篇 |
2015年 | 21篇 |
2014年 | 46篇 |
2013年 | 76篇 |
2012年 | 42篇 |
2011年 | 45篇 |
2010年 | 41篇 |
2009年 | 41篇 |
2008年 | 34篇 |
2007年 | 43篇 |
2006年 | 28篇 |
2005年 | 25篇 |
2004年 | 28篇 |
2003年 | 30篇 |
2002年 | 13篇 |
2001年 | 10篇 |
2000年 | 9篇 |
1999年 | 8篇 |
1998年 | 14篇 |
1997年 | 11篇 |
1996年 | 10篇 |
1995年 | 11篇 |
1994年 | 16篇 |
1993年 | 7篇 |
1992年 | 8篇 |
1991年 | 7篇 |
1990年 | 9篇 |
1989年 | 12篇 |
1988年 | 6篇 |
1987年 | 7篇 |
1986年 | 4篇 |
1985年 | 9篇 |
1984年 | 10篇 |
1983年 | 3篇 |
1982年 | 7篇 |
1981年 | 3篇 |
1980年 | 6篇 |
1979年 | 2篇 |
1977年 | 1篇 |
1976年 | 4篇 |
排序方式: 共有1022条查询结果,搜索用时 15 毫秒
31.
32.
Fadwa Al-Ghalib Al-Sharif Osama Hussien Al-Jiffri Shehab Mahmoud Abd El-Kader Eman Mohamed Ashmawy 《African health sciences》2014,14(1):11-16
Background
Patients with hemophilia A have low bone density than healthy controls. It is now widely recognized that physical activity and sports are beneficial for patients with hemophilia.Objective
To compare the effects of mild and moderate intensity treadmill walking exercises on markers of bone metabolism and hand grip strength in male patients with moderate hemophilia A.Material and Methods
Fifty male patients with moderate hemophilia, and age range from 25 to 45 years. The subjects were randomly assigned into 2 equal groups; the first group (A) received moderate intensity aerobic exercise training. The second group (B) received mild intensity aerobic exercise training.Results
There was a 32.1% and 24.8% increase in mean values of serum calcium and hand grip strength respectively and 22.7 % reduction in mean values of parathyroid hormone in moderate exercise training group (A). While there was a 15.1 % and 15 % increase in mean values of Serum Calcium and Hand grip strength respectively and 10.3 % reduction in mean values of parathyroid hormone in mild exercise training group(B). The mean values of serum calcium and hand grip strength were significantly increased, while the mean values of parathyroid hormone were significantly decreased in both groups . There were significant differences between mean levels of the investigated parameters in group (A) and group (B) after treatment.Conclusion
Moderate intensity aerobic exercise training on treadmill is appropriate to improve markers of bone metabolism and hand grip strength in male patients with hemophilia A. 相似文献33.
Flora Peyvandi Gili Kenet Isabell Pekrul Rajiv K. Pruthi Peter Ramge Michael Spannagl 《Journal of thrombosis and haemostasis》2020,18(6):1242-1255
The advent of extended half‐life (EHL) recombinant clotting factors and innovative non‐factor replacement therapeutics, such as emicizumab, offers several advantages over existing products for the prophylactic treatment of people living with hemophilia (PwH). These include low annual bleeding rates with less frequent dosing, higher trough plasma concentrations, and a more convenient route of administration. However, increasing use of these therapies poses challenges to clinicians and coagulation laboratories due to the lack of standardized assays for monitoring of hemostatic parameters, and the potential for misinterpretation of test results, which may jeopardize patient safety. Definitive diagnosis of hemophilia and treatment monitoring is reliant on demonstrating factor VIII (FVIII; hemophilia A) or factor IX (FIX; hemophilia B) deficiency using a functional coagulation assay. The most frequently used assays are based on activated partial thromboplastin time, using a one‐stage or two‐stage process. While one‐stage and chromogenic assays have performed well with human‐derived FVIII and FIX and full‐length recombinant products, EHL recombinant factors are heterogeneous in structure and mode of action and therefore show wide variation in activity levels between different one‐stage assays, and between one‐stage and chromogenic assays. In the context of the recommended stepwise approach for laboratory diagnosis of hemophilia, we examine the diagnostic challenges associated with the use of EHL factors and novel non‐factor therapeutics and consider the optimal diagnostic approach in PwH who are receiving these treatments. Ultimately, accurate diagnostic solutions are a prerequisite for personalized therapy to minimize treatment burden and improve quality of life in PwH. 相似文献
34.
María Isabel Rivas‐Pollmar María Teresa lvarez‐Romn Nora V. Butta‐Coll Mnica Martín Salces Sara García‐Barcenilla Victor Jimnez‐Yuste 《Journal of thrombosis and haemostasis》2020,18(9):2202-2204
COVID‐19 can be associated with coagulopathy (CAC, COVID‐19‐associated coagulopathy) with a high prothrombotic risk based on an intense inflammatory response to viral infection leading to immunothrombosis through different procoagulant pathways. Emerging evidence suggests that the use of heparin in these patients could be associated with lower mortality. Emicizumab is a bispecific humanized monoclonal antibody that bridges activated factor IX and factor X, thereby restoring the function of missing factor VIIIa in hemophilia A. The use of emicizumab has been associated with thrombotic events in patients who also received high cumulative amounts of activated prothrombin complex concentrates. Although this risk is extremely low, there is a lack of evidence on whether CAC increases the thrombotic risk in patients on emicizumab prophylaxis. We present the case of a patient with severe hemophilia A in prophylaxis treatment with emicizumab; due to the potential thrombotic risk we decided to administer low molecular weight heparin as prophylaxis treatment without any thrombotic or bleeding complications. 相似文献
35.
36.
37.
Donna M. DiMichele Martin E. Lasak Connie H. Miller 《American journal of hematology》1996,51(2):99-103
Factor VIII (FVIII) replacement by continuous infusion has been advocated as a cost-effective method for maintaining stable plasma levels of FVIII in the hemophilia A patient during surgery or life-threatening hemorrhage. Continuous delivery of monoclonal or recombinant FVIII concentrates to our pediatric patients using a traditional delivery system (dilution in normal saline of 2–10 U/ml infused at a rate of 20 ml/hr) has frequently yielded higher than expected factor usage to achieve desired levels and unexpected variability in plasma levels under presumed steady-state conditions. To determine if diminished in vitro FVIII recovery was responsible for these observations, a study of four ultrapure concentrates during 8 hr of in vitro continuous delivery was performed using four delivery systems. When reconstituted concentrate was added to normal saline in polyvinylchloride bags at a concentration of 10 U/ml (method IA), monoclonal products showed a stable recovery of 84–109% of time 0 levels. Recombinant product recovery dropped to 57–76% of time 0 levels before reapproximating the time 0 level at 2 hr. The addition of 10 mg/ml human albumin to the bags (method IB) did not improve recoveries. When reconstituted concentrate was delivered undiluted (method IIA), the early drop in recombinant recovery was eliminated; stable recovery of 78–117% of time 0 level was achieved with all products. In using method IA, a large discrepancy was seen between the actual time 0 recoveries and those expected based on vial assays, most striking for recombinant products (49–57% of expected). Method IIA allowed 75–90% recovery; addition of 20 mg/ml albumin of reconstituted but undiluted concentrate (method IIB) maximized recovery at 85–98% of expected. © 1996 Wiley-Liss, Inc. 相似文献
38.
Inversions between a gene A copy within intron 22 of the factor VIII gene and additional copies outside the factor VIII gene were found in 49 families with hemophilia A. Inversion patterns were that of recombination with a distal gene A copy in 34, a proximal copy in 14, and a third (variant) copy in one. Baseline factor VIII clotting activity levels were <1% of normal in 43 and 1% in 6. No inversion was detected in 61 other families whose affected members had ≤1% activity levels nor in 42 families with moderately severe hemophilia A and 2–5% baseline levels. Both high titer and low level alloantibody inhibitors were found in patients with or without an inversion. Of 13 high titer inhibitors, 8 were persistent and 1 of these patients had an inversion. Of 5 that responded to daily factor VIII infusions, 4 were in patients with gene inversions. Of the 49 families with an inversion, the occurrence of hemophilia was isolated in 30 and the mother was a carrier in the 25 in which additional family members were informative. In three of these families with isolated occurrence, the maternal grandmother was a carrier whereas in three others a de novo mutation occurred in the maternal grandfather's factor VIII gene. Screening for gene inversions in patients with severe (or “borderline” severe) hemophilia A provides a direct marker of the mutation in 45% of families. It is useful even if there is no living affected member and in predicting the likely severity of an infant in which there are no reliable baseline clotting activities, including 70% of families with isolated occurrences of hemophilia A. © 1996 Wiley-Liss, Inc. 相似文献
39.